Videos

Metastatic Castration-Resistant Prostate Cancer Issue 2

Metastatic Castration-Resistant Prostate Cancer Issue 2

Benjamin G. Neel, MD, faculty, Department of Medicine, Perlmutter Cancer Center, NYU School of Medicine, discusses the future of immunotherapy and how it could play a role in various tumor types.

Gynecologic Cancers

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.

James M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).

Robert L. Coleman, MD, FACOG, FACS, professor, Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, vice chair, Clinical Research, The University of Texas MD Anderson Cancer Center, discusses the results of the ARIEL2 trial, a phase II study to identify patients with ovarian cancer likely to respond to rucaparib using tumor genetic analysis.

Oliver Sartor, MD, medical director, Tulane Cancer Center, discusses the United States experience of the Expanded Access Program (EAP) on radium-223 for prostate cancer.